Aktiechat - investeringstips

	11/5 16:26 af Jan Van de Winkel	This is the majority of the frontline market which could grow due to new treatments becoming available to frontline patients.
	11/5 16:26 af Bulder	When can we expect data from the Centaurus trial?
	11/5 16:26 af Jan Van de Winkel	This is the smoldering trial - maybe at a medical conference in the second half of the year.
	11/5 16:27 af jkj	what is the time frame for application submitted in Japan for daratumumab
	11/5 16:27 af Jan Van de Winkel	Usually you expect about a year from submission for approval. We submitted in late December last year.
	11/5 16:27 af jkj	What is the time frame for the lawsuit whit Morphosys
	11/5 16:28 af Jan Van de Winkel	We cannot comment on ongoing litigation
	11/5 16:28 af Bulder	Is it your intention to ask for approval of dara+KRd frontline, since the data will be presented orally at ASCO?
	11/5 16:29 af Jan Van de Winkel	this is a small set of patients, and so this is highly unlikely.
	11/5 16:29 af Jedi	Have interim analyses been planned for the Maia DRd frontline study? If yes, how many events need to take place before the interim analysis?
	11/5 16:30 af Jan Van de Winkel	Yes there is a prescheduled interim planned for Maia.
	11/5 16:30 af Jedi	What is the estimated time line for interim data from the Maia study?
	11/5 16:30 af Jan Van de Winkel	We would expect interim data in 2018
	11/5 16:31 af Sukkeralf	Jan you mentioned in yesterdays CC that you already see activity with Humax-AXL ADC - is that at a lower dose than expected ?
	11/5 16:32 af Jan Van de Winkel	The trial is progressing very well and we are swiftly moving through the dose escalation.
	11/5 16:32 af Helge Larsen/PI-redaktør	Great. We have 2 questions more left for you.
	11/5 16:32 af Jan Van de Winkel	Looking forward.
	11/5 16:32 af bongobob	Are you considering a spin off to capitalize on technologies?
	11/5 16:33 af Jan Van de Winkel	Our technologies support the advancement of new exciting and differentiated products - we will continue to license access to our proprietary technologies.
	11/5 16:34 af bongobob	How many FTE’s do you plan for in the sales/commercial side?
	11/5 16:34 af Jan Van de Winkel	We are anticipating controlled in all three of our sites and will expand departments carefully, depending on the needs of product development and markets served.
	11/5 16:35 af Jan Van de Winkel	(controlled growth)
	11/5 16:36 af Helge Larsen/PI-redaktør	Jan and David. Thank You for joining us and thank you for the many fullfilling answers to our questions. We wish you a very good presentation at ASCO. We look forward to to seeing you back here on ProInvestor after Q2. :-)
	11/5 16:36 af Jan Van de Winkel	Thank you, for an energizing online chat. Look forward to next quarter.

	11/5 16:37 af Helge Larsen/PI-redaktør	This session is ended.